A detailed history of Palumbo Wealth Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Palumbo Wealth Management LLC holds 5,268 shares of PTGX stock, worth $445,725. This represents 0.09% of its overall portfolio holdings.

Number of Shares
5,268
Previous 7,530 30.04%
Holding current value
$445,725
Previous $416,000 16.11%
% of portfolio
0.09%
Previous 0.14%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

SELL
$49.7 - $67.42 $112,421 - $152,504
-2,262 Reduced 30.04%
5,268 $349,000
Q2 2025

Jul 15, 2025

BUY
$40.89 - $56.37 $307,901 - $424,466
7,530 New
7,530 $416,000
Q3 2024

Oct 28, 2024

BUY
$33.72 - $47.33 $175,714 - $246,636
5,211 New
5,211 $234,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $4.15B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Palumbo Wealth Management LLC Portfolio

Follow Palumbo Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palumbo Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Palumbo Wealth Management LLC with notifications on news.